BRIEF—bluebird bio names Alison Finger as CCO

US biotech bluebird bio, a clinical-stage company committed to developing potentially transformative gene therapies for severe genetic diseases and T cell-based immunotherapies for cancer, today appointed Alison Finger as chief commercial officer.

In this role, Ms Finger will be responsible for shaping and delivering an integrated global commercial strategy to make bluebird’s gene therapies broadly accessible to patients. She will oversee all commercial strategy and operations, access management, including pricing, reimbursement and health outcomes, as well as patient operations.

Ms Finger has been promoted to chief commercial officer after joining bluebird as senior vice president, marketing and product launch in August of 2015. Prior to joining bluebird, she spent 21 years at Bristol-Myers Squibb.

“Alison’s leadership in commercial planning and strategy has been a tremendous asset as we transition to a fully-integrated commercial-stage company,” said Nick Leschly, chief bluebird. “As bluebird continues to expand and anticipates regulatory filings for three programs in the next two years, Alison’s belief and commitment to our patient-driven mission, along with her outstanding commercial expertise, will help ensure our products find their way to patients who will potentially benefit from the transformational gene therapies we are developing.”